LifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Twitter outputted an error:
Invalid or expired token..
Invalid or expired token..
LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients
Seed funding will be used to scale the solution through the application of machine learning
AbbVie acquires LifeArc portfolio company DJS Antibodies
AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS
LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million
First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…
LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases
Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.
LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science
Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.
10 new data-driven health companies selected for KQ Labs accelerator programme
10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…
LifeArc invests in company developing personalised drug and digital combination treatments
LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.